Mark A Socinski of AdventHealth Cancer Institute is today's featured KOL from SpeakerBook

August 4, 2020

By: Stephen

Today's Featured key opinion leader (KOL) is Mark A Socinski a board-certified, fellowship-trained medical oncologist, Mark is the Executive Medical Director of the AdventHealth Cancer Institute. Today we are going to use SpeakerBook to learn more about Mark A Socinski and some of his popular speaking engagements from the 2018 Sunshine Act open payments data.

Mark overall is one of the most active speakers in the pharmaceutical industry. Mark has had speaking engagements for the following products.

Mark A Socinski 2018 Speaker Program Totals:

• Tecentriq - 12 Speaking Programs

• Abraxane: - 11 Speaking Programs

• Opdivo - 10 Speaking Programs

• Imfinzi - 10 Speaking Programs

• Tagrisso: - 10 Speaking Programs

• Retacrit - 2 Speaking Programs

• Mekinist - 1 Speaking Program

• Avastin: - 1 Speaking Program

If we take a look at Mark’s Pharma speaker programs Tecentriq, Abraxane, Opdivo, Imfinzi, and Tagrisso make up the majority of his speaking engagements with Tecentriq amounting to 20.7% of Mark’s total Pharma industry payment of $369,223 dollars. Imfinzi makes up 14.9% while Tagrisso, Abraxane, and Opdivo make up about 11% of Mark’s total Pharma payments.

March of 2018 was his most active speaking month with 11 Pharma Speaking Program engagements that totaled $15,037. June was Mark's most profitable month totaling $33,000 for 10 speaking engagements. Tecentriq from Genentech was around ⅓ of June's total Pharma payments making up $10,560 for 2 speaking events.

Not only is Mark A Socinski an engaging KOL speaker he actively consults for some of the top pharmaceutical companies in the industry. Mark has consulted for Lilly USA, Genentech, Takeda Pharmaceuticals, Novartis Pharmaceuticals, Astrazeneca Pharmaceuticals , Roche, Pfizer, Chugai Pharmaceuticals, Celegene, and Merck.

These engagements make Mark a high profile KOL that is valued and respected in the Oncology pharmaceutical sector. SpeakerBook can help you discover and then better understand any KOL or HCP in the pharmaceutical industry.

SpeakerBook keeps up to date with active KOLs speaking engagements and news articles. Mark has been featured in the following publications. Use SpeakerBook to stay up to date with the latest news on the active KOLs that matter to you and your company's objectives.

Mark A Socinski news and editorial events from SpeakerBook:

• Managing cancer care during COVID-19: 5 oncologists, leaders weigh in

• Bevacizumab (Avastin®) in Cancer Treatment: A Review of 15 Years of Clinical Experience and Future Outlook - Beyond the Abstract

• Socinski Details Immunotherapy Trials for the Treatment of Advanced Nonsquamous NSCLC

• Dr. Socinski on Current State of Treatment in NSCLC

• New Quality Initiative for Patients With Advanced Lung Cancer Improves Care, Coordination

• Tumor-Agnostic Testing in a Non-Small Cell Lung Cancer Pathway

• Physicians’ Education Resource® Presents the 17th Annual Winter Lung Cancer Conference™

• AdventHealth launches first-of-its-kind immunotherapy treatment, clinical trial for specific blood cancer patients

• AdventHealth brings CART T-cell therapy to Central Florida lymphoma patients

• Atezolizumab plus chemotherapy improves survival in lung cancer subtype

SpeakerBook has highlighted Mark A Socinski of AdventHealth as today's featured Oncology Key Opinion Leader. SpeakerBook has done a good job at breaking down Mark’s speaking engagements so that you can better understand the RX products and organizations that Mark interacts with. You can use the SpeakerBook app to learn more about Mark A Socinski or any other KOL that you would like more information on.

Download SpeakerBook in the iOS app store today.

---